Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation No phase listed Observational

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

ClinicalTrials.gov ID: NCT05962398

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05962398. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).

Study identification

NCT ID
NCT05962398
Recruitment status
Enrolling by invitation
Study type
Observational
Phase
Not listed
Lead sponsor
CSL Behring
Industry
Enrollment
56 participants

Conditions and interventions

Conditions

Interventions

Genetic

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 30, 2023 (Actual)
Primary completion
Mar 23, 2035 (Estimated)
Completion
Mar 23, 2035 (Estimated)
Last update posted
Jul 18, 2025

2023 – 2035

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
10-15 Phoenix Childrens Hospital Phoenix Arizona 85016 —
10-14 Arkansas Children's Hospital - Pharmacology Little Rock Arkansas 72202 —
10-22 Orthopaedic Institute for Children Los Angeles California 90007 —
10-21 Children's Hospital of Los Angeles Los Angeles California 90027 —
10-63 UC Davis Medical Center Sacramento California 95817 —
10-12 University of California, San Diego (UCSD) San Diego California 92121 —
10-25 University of Colorado Denver Aurora Colorado 80045 —
10-19 University of South Florida Tampa Florida 33612 —
10-10 University of Michigan Medical Center Ann Arbor Michigan 48109 —
10-16 University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 —
10-18 Oregon Health & Science University Portland Oregon 97239 —
10-20 Vanderbilt University Medical Center Nashville Tennessee 37232 —
10-28 University of Texas Health Science Center Houston Texas 77030 —
10-26 University of Utah Salt Lake City Utah 84108 —
10-62 Washington Institute for Coagulation Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05962398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2025 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.